Clinical Advances in Anaphylaxis and Mast Cell Disorders
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 94
Special Issue Editor
2. Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden
Interests: allergy immunotherapy; anaphylaxis; mastocytosis; mast cell activation syndromes; severe asthma
Special Issue Information
Dear Colleagues,
Mast cells (MCs) are multifunctional, granulated, stationary cells that reside in almost all vascularized tissues. Upon activation, MCs degranulate and release a large array of mediators. Inappropriate release of these mediators may occur in a number of pathologic conditions and can cause a range of symptoms from mild to severe to life-threatening.
Evidence in the recent literature suggests that mast cell activation disorders have a broad spectrum of presentation and may have clonal or non-clonal etiologies. When mediator release is excessive and involves ≥2 organ systems, anaphylaxis may occur. Mast cell activation syndrome (MCAS) is another special variant of systemic MC activation, characterized by severe, recurrent, and episodic symptoms caused by abrupt MC mediator release. Patients with MCAS often present with symptoms of anaphylaxis. Furthermore, mastocytosis is a clonal disorder of MCs and may often present with anaphylaxis and MCAS. However, in some cases, even proliferative and accumulative features of MCs in mastocytosis can account for the symptoms and progression of this disease. In addition, a newly identified genetic trait, hereditary alpha-tryptasemia, may influence susceptibility to severe anaphylaxis.
The aim of this Special Issue is to provide a comprehensive overview of the advances in the diagnosis and management of anaphylaxis and mast cell disorders. Therefore, we invite you to contribute original research articles, review articles, or shorter perspective articles focused on the latest developments in this intriguing field.
Dr. Theo Gülen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anaphylaxis
- mastocytosis
- mast cell activation syndrome
- tryptase
- mast cell activation
- mast cell mediators
- KIT D816V
